Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock.
Gallup reported 11% of U.S. adults are currently taking GLP-1 weight-loss drugs, up from 3% in 2024, and 15% have used them at some point. Eli Lilly (LLY) and Novo Nordisk (NVO) are cited as key makers. Lilly said Q1 Mounjaro sales were $8.7B and Zepbound $4.2B, total revenue $19.8B, and raised 2026 guidance to $82.2B-$85B.
How this was made
The 30-second read
Why it matters
For Lilly, the article ties category adoption to company-specific momentum: tirzepatide sales, raised 2026 revenue guidance, and an oral weight-loss product becoming available in early April.
Market read
The newest actionable elements are Lilly’s raised full-year 2026 revenue guidance and the early-April availability of its oral GLP-1 weight-loss drug.
What to watch
Valuation is described as very high (P/E multiples), so even good news can face multiple-compression risk if growth normalizes or oral uptake is slower than expected.
Background
Gallup reports GLP-1 usage and awareness rising sharply versus 2024, framing a broader demand tailwind for GLP-1 manufacturers.
Ticker impact
Article cites Gallup GLP-1 adoption and links it to Lilly’s tirzepatide growth, including raised 2026 revenue guidance and oral drug rollout.
Near-term bias to upside as investors price continued tirzepatide momentum and oral-option adoption; volatility likely given valuation.
The text provides concrete company datapoints (Q1 sales, combined tirzepatide revenue, and raised full-year guidance) and a specific product catalyst (Foundayo approval and early April availability). The Gallup adoption figures are supportive but not a direct sales print.
Market effects
Reinforces GLP-1 category demand narrative, potentially lifting sentiment across obesity/diabetes drug makers.
Primarily US demand read-through from Gallup polling; could influence US healthcare growth multiples.
Category adoption trend can affect global GLP-1 supply/demand expectations and competitive dynamics.
Counterpoint
Polling-based adoption growth may not translate 1:1 into Lilly’s incremental prescriptions or pricing, especially if payer restrictions or competition intensify.
Key entities
- public_companyEli Lilly
Tirzepatide franchise (Mounjaro, Zepbound) and oral GLP-1 weight-loss drug Foundayo; raised 2026 revenue guidance per article.
- polling_organizationGallup
Reported GLP-1 usage and awareness among US adults, used as demand read-through.
